Is it Possible to Protect Pediatric Research Subjects without Blocking Appropriate Research?

Journal of Pediatrics

Volumn 152, Issue 4, 2008, Pages 467-470

  Wendler, David ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; CHILD CARE; ETHICS; EVALUATION; EXAMINATION; GASTROESOPHAGEAL REFLUX; HUMAN; INTERVENTION STUDY; MEDICAL RESEARCH; PEDIATRICS; PERFORMANCE; PHOTON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY; STANDARD;

EID: 40749111108     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.09.027     Document Type: Note

References (19)

1. Regulations on new therapy and human experimentation. Reprinted in: International Digest of Health Legislation 31 (1980) 408-411
2. Vollmann J., and Winau R. Informed consent in human experimentation before the Nuremberg code. BMJ 313 (1996) 1445-1449
3. The Nuremberg Code. JAMA 276 (1996) 1691
4. Kauffman R.E. Clinical trials in children: problems and pitfalls. Paediatr Drugs 2 (2000) 411-418
5. Caldwell P.H.Y., Murphy S.B., Butow P.H., and Craig J.C. Clinical trials in children. Lancet 364 (2004) 803-811
6. Roberts R., Rodriquez W., Murphy D., and Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290 (2003) 905-911
7. Berlin I., and Gorelick D. The French law on "protection of persons undergoing biomedical research"; implications for the U.S. J Law Med Ethics 31 (2002) 434-441
8. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good clinical practice: consolidated guidance. Published in Federal Register 62 (1997) 25692 May 9
9. US Department of Health and Human Services. Code of Federal Regulations. 45 CFR 46, subpart D.
10. US Food and Drug Administration. Code of Federal Regulations. Title 21, 50.25. Vol 1, revised April 1, 2005.
11. Kopelman L.M. Minimal risk as an international ethical standard in research. J Med Philos 29 (2004) 351-378
12. Ross L.F., and Nelson R.M. Pediatric research and the federal minimal risk standard. JAMA 295 (2006) 759-760
13. Resnik D.B. Eliminating the daily risks standard from the definition of minimal risk. J Med Ethics 31 (2005) 35-38
14. Wendler D., and Glantz L. A new standard for assessing the risks of pediatric research: pro and con. J Pediatr 150 (2007) 579-582
15. Kummar S., Kinders R., Rubinstein L., Parchment R.E., Murgo A.J., Collins J., et al. Compressing drug development timelines in oncology using phase "0" trials. Nat Rev Cancer 7 (2007) 131-139
16. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 317 (1987) 141-145
17. Eddy D.M. Health system reform. Will controlling costs require rationing services?. JAMA 272 (1994) 324-328
18. Daniels N. Just health care (1995), Cambridge University Press, New York, N.Y
19. Institute of Medicine. Ethical conduct of clinical research involving children. In: Field M.J., and Berman R.E. (Eds) (2005), The National Academies Press, Washington, DC